Attention ! This investment does not fall within the scope of AMF control. No license and no prospectus is required for this activity
This information is not intended for residents of the United Kingdom, United States, Australia, Canada or Japan. See appendix for full disclaimer
TME PHARMA LAUNCHES A FULLY GUARANTEED CAPITAL INCREASE OF €2.7 M WITH PREFERENTIAL SUBSCRIPTION RIGHTS (DPS) FOR SHARES ASSOCIATED WITH SUBSCRIPTION WARRANTS (ABSA) AND ANNOUNCES THE PURCHASE OF PART OF ITS CONVERTIBLE DEBT
• The guaranteed amount of the transaction extends cash flow visibility beyond the regulatory milestones of the first quarter of 2024.
• This financial visibility will allow TME Pharma to submit and then receive comments from the FDA on its INDs and applications for expedited regulatory review.
• Current shareholders benefit from preferential subscription rights to participate in the capital increase by issuing shares accompanied by subscription warrants.
• Repurchase of almost half of the convertible debt in circulation and blocking of the residual amount until April 1, 2024.
• New share subscription warrants issued with the possibility of raising an additional 2.2 million euros and extending cash flow visibility until September 2024 in the event of full exercise.